EHA 2015 | ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma
Jesús San Miguel
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicenter, open-label, randomized, phase 3 ENDEAVOR trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed multiple myeloma.
Related videos
1:53 The European CAR T-Cell Meeting: facilitating discussion to advance the field
Nicolaus Kröger
3:01 Academic vs. commercial CAR T-cell products
Arnon Nagler
1:55 CRISPR/Cas9 edited T-cells in MM and sarcoma
Bruce Levine
1:21 2nd European CAR T-Cell Meeting: Christian Chabannon's highlights
Christian Chabannon
5:32 The complex journey of CAR T-cell therapy
Mohamad Mohty
